| Observed cases | Non-responder imputation, n (% of 154 pts)† | |||||
|---|---|---|---|---|---|---|
| Cumulative VDZ exposure (wks) | GEMINI OLE study wk | N | Clinical response, n (%*) | Clinical remission, n (%*) | Clinical response | Clinical remission |
| 52 | 0 | 154 | 146 (95) | 135 (88) | 146 (95) | 135 (88) |
| 80 | 28 | 145 | 134 (92) | 127 (88) | 134 (87) | 127 (82) |
| 104 | 52 | 136 | 124 (91) | 120 (88) | 124 (81) | 120 (78) |
| 128 | 76 | 127 | 119 (94) | 117 (92) | 119 (77) | 117 (76) |
| 152 | 100 | 118 | 114 (97) | 110 (93) | 114 (74) | 110 (71) |
| 200 | 148 | 108 | 104 (96) | 100 (93) | 104 (68) | 100 (65) |
| 248 | 196 | 63 | 62 (98) | 57 (90) | 62 (40) | 57 (37) |
*Percentage of observed cases (N) at study visit
†Pts without available data included as non-responders/remitters